Our Customers

Trusted by Scientists

According to our Customers, siTOOLs Biotech is most valued for the high efficiency, reliable results and detailed design of our reagents. They also value the excellent technical support provided both in the form of troubleshooting advice and in-house validation experiments.

Dr. Derek Welsbie
Assistant Professor
University of California San Diego, USA

"Our lab uses arrayed, high-throughput functional genomic screening in primary neurons to identify potential neuroprotective drug targets. Having tested over 75,000 siRNA sequences, it is quite apparent that off-target effects dominate siRNA-mediated phenotypes. In contrast, in our hands, siPOOLs have much greater predictive power in that phenotypes we see with these (and we have tested approximately 15) can be reproduced using cells containing conventional knockouts for the same genes. We now routinely use siPOOLs and are moving away from single siRNAs."

"In our group, siPOOLs by siTOOLs for specific and sustained gene knockdown are used for several years now. We have tested and worked with approx. 35-40 siPOOLs by now. siPOOLs are easy in handling, and mostly effective in transient specific gene knockdown experiments. We could not detect any side effects, and the available control (control siPOOL) has no side effects on function or gene expression that we can detect as compared to untransfected cells. As compared to other commercially available single siRNAs, siPOOLs are much more effective, therefore, we can use less amounts of siPOOLs, which is very cost-efficient. Moreover, xenograft tumor models demonstrated that specific gene knockdown is sustained, i.e. gene knockdown is longer as compared to single siRNAs. siPOOLs are easy in handling, we use Lipofectamine 2000 or RNAimax as described by the manufacturer. The client service offered by siTOOLs is excellent. We get advice and even hands-on support immediately whenever necessary."

Dr. med. Peter Dietrich
Post-doctoral Scientist
Institute of Biochemistry Prof. Dr. Anja Katrin Bosserhoff Group FAU, Germany

Ms. Jasmine Barra
PhD Student
Lab for Molecular Cancer Biology
Prof. Dr. Chris Marine Group
VIB Center for the Biology of Disease
KU Leuven, Belgium

"For our research purpose the use of siPOOLs proved to be a key choice. We could overcome the major issues of both cell toxicity and off target effects we observed using GAPMERs.
In our hands the siPOOLs performed always with high reproducibility, allowing us to increase the efficiency of knock down of our target of interest, despite the poor results given by standard siRNA approaches.
Moreover siTOOLs could custom design for us isoform-specific siPOOLs that allowed us to address in a more specific way our biological questions."

"Our Cancer Drug Discovery group uses siRNA technology on a routine basis for target validation experiments. To guarantee robustness of target validation processes we use several independent siRNAs or siRNA pools for the same target of interest. We often observe however, a discrepancy between these reagents in produced cancer phenotypes due to off-target effects, which frequently delivered false-positive results. By using siPOOLs, we were able to overcome this discrepancy. siPOOLs are highly target-specific and show an efficient knockdown of the target already in the range of low nanomolar concentrations. Another advantage of siPOOLs is that they are able to distinguish very specifically between highly homologous transcript sequences. We are very happy with those siPOOLs, which helped to avoid waste of time and costs within the drug discovery process by producing reliable data."

Dr Mona Malz
Senior Scientist
German Cancer
Research Centre (DKFZ)
Heidelberg, Germany

Ferran Araujo
Graduate Student
Vall d'Hebron Research Institute (VHIR) Barcelona, Spain

"Using siPOOLs we achieved a very good silencing of our genes. Moreover, the siRNAs work at very low concentrations, helping us avoid potential off-target effects and cytotoxicity in our cells."

Subscribe to Newsletter

For Product News, Exclusive Promotions, Blog and Research Highlights. By clicking subscribe you agree to the privacy policy.

Please Enter Your Email Address to recieve our Newsletter:

Follow us

For Latest Updates